palivizumab /kg

PreclinicalMonoclonal antibody

palivizumab /kg is one of 6 biologic programs targeting Respiratory Syncytial Virus (RSV). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Syncytial Virus (RSV)Active, not recruiting

Respiratory Syncytial Virus (RSV)Preclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Respiratory Syncytial Virus (RSV)

#DrugCompanyPhaseTrials

BEYFORTUS

Sanofi

Approved

1 2

Rsvpref

Pfizer

Phase 3

2 3

Mrna-1345

Moderna

Phase 3

7 4

Rsvpref Vaccine

Pfizer

Phase 3

1 5

Mrna-1365

Moderna

Phase 1

1 6

palivizumab /kg

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Respiratory Syncytial Virus (RSV)

NCT06851806

Clinical

Trials by Indication[1]

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00113490·136 enrolled

Respiratory Syncytial Virus (RSV)1 trial

A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06851806·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for palivizumab /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — palivizumab /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for palivizumab /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

palivizumab /kg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Immunogenicity1 trial

Respiratory Syncytial Virus (RSV)1 trial

References

Drug Info

Quick Facts

Related News